A clash of financial forces, both good and bad, largely offset one another Wednesday as executives at medical device maker Boston Scientific sought to emphasize a positive new product approval and ...
HOLLYWOOD, FL—The gap in outcomes between the Eluvia (Boston Scientific) and Zilver PTX (Cook Medical) drug-eluting stents is especially pronounced for diabetic patients being treated for ...
SAN DIEGO, CA—In the first randomized, head-to-head comparison of two drug-eluting stents in patients with femoropopliteal disease, the Eluvia paclitaxel-eluting stent (Boston Scientific) came out ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Boston Scientific Corporation BSX recently announced the receipt of a New Technology Add-on Payment (NTAP) for its Eluvia Drug-Eluting Vascular Stent System from the U.S. Centers for Medicare and ...
LAS VEGAS and MARLBOROUGH, Mass., Oct. 6, 2021 /PRNewswire/ -- Today, Boston Scientific Corporation (NYSE: BSX) announced positive data for the Eluvia™ Drug-Eluting Vascular Stent System (Eluvia stent ...
Shares of Boston Scientific were slightly up on Monday (about 1.44%), as the Marlborough, Mass.-based company announced it received FDA approval for the Eluvia Drug-Eluting Vascular Stent System. The ...
MARLBOROUGH, Mass., Feb. 22, 2016 /PRNewswire/ -- Boston Scientific (NYSE: BSX) today announced that the Eluvia™ Drug-Eluting Vascular Stent System has received CE Mark and is commencing ...
Regulators in the United States have approved the Eluvia Drug-Eluting Vascular Stent System (Boston Scientific) for the treatment of peripheral artery disease (PAD), based on the ...
The skinny spring trapped inside the tube on the conference table in front Jay Kokate may someday prevent thousands of diabetic patients from having their legs and feet amputated. At least, that's the ...
Boston Scientific Corporation BSX recently announced the receipt of a New Technology Add-on Payment (NTAP) for its Eluvia Drug-Eluting Vascular Stent System from the U.S. Centers for Medicare and ...
Boston Scientific Corporation BSX recently announced favorable data supporting the Eluvia Drug-Eluting Vascular Stent System (Eluvia stent) during a late-breaking clinical trial presentation at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results